5,477 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the fourth quarter, Holdings Channel reports. The firm purchased 5,477 shares of the company’s stock, valued at approximately $898,000.

Several other institutional investors also recently bought and sold shares of the business. Darwin Wealth Management LLC purchased a new position in shares of Zoetis during the 3rd quarter valued at approximately $31,000. First Personal Financial Services acquired a new position in Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP purchased a new position in Zoetis during the third quarter valued at $33,000. Dunhill Financial LLC grew its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Quarry LP increased its stake in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ZTS. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. JPMorgan Chase & Co. raised their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $211.89.

Zoetis Trading Up 2.6 %

Shares of ZTS stock opened at $173.07 on Tuesday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company’s 50-day moving average price is $170.10 and its 200-day moving average price is $179.75. The stock has a market cap of $78.08 billion, a price-to-earnings ratio of 32.53, a PEG ratio of 2.57 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.36 EPS. As a group, equities analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.16%. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.